Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ReNeuron appoints new chief medical officer based in recently established US office

The AIM-listed firm said Dr Richard Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity
Prior to joining ReNeuron, Beckman was the chief medical officer of several innovative biotech and device firms

ReNeuron Group PLC (LON:RENE) has announced the appointment of Dr Richard Beckman as chief medical officer, to lead the company’s clinical and medical affairs team based in its recently established US office in Boston.

The AIM-listed firm said Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity.

WATCH: Reneuron’s Michael Hunt updates on product development

The cell-based therapeutics specialist said Beckman brings to ReNeuron more than 25 years of executive and consultancy experience in drug and device development.

Prior to joining ReNeuron, he was the chief medical officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech.

He also had leadership roles at Alcon, Lux Bio, Becton Dickinson and Co (NYSE:BDX) and Allergan PLC (NYSE:AGN).

Olav Hellebø, chief executive officer at ReNeuron, said: "His many years’ experience in medical practice and industry in the US will be invaluable to us as we build out our Boston team and increase our clinical activities in the US.”  

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use